Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)

When we eat, our bodies convert unused energy into fats called triglycerides, which circulate in the bloodstream. While everyone has some triglycerides, having extremely high levels is known medically as severe hypertriglyceridaemia. This condition often causes no everyday symptoms, but it significantly increases the risk of acute pancreatitis. Pancreatitis is a severe, sudden inflammation of the pancreas that often requires emergency hospital treatment.

Managing very high blood fats through diet and currently available medicines can sometimes be difficult. The SHASTA-4 study is exploring a new medicine called plozasiran. Plozasiran is designed to help the body break down and clear fats from the bloodstream more effectively. Researchers want to see if this treatment can bring blood fats down to much safer levels.

This is a Phase 3 study, which means the drug has already passed early safety checks in smaller groups of people. Researchers now need to test it in a larger group of adults to confirm how well it works and to watch for any unexpected side effects. To make the results fair and reliable, plozasiran is being compared against a placebo, which looks identical but has no active ingredients.

By taking part, participants help doctors learn whether plozasiran can become a useful new treatment option. If successful, this medicine could give people with very high blood fats a reliable way to protect their pancreas and support their long-term health.